Memantine and brain atrophy in alzheimer's disease: A 1-year randomized controlled trial

Journal of Alzheimer's Disease

Volumn 29, Issue 2, 2012, Pages 459-469

  Wilkinson, David ^a   Fox, Nick C ^b   Barkhof, Frederik ^c   Phul, Ravinder ^d   Lemming, Ole ^e   Scheltens, Philip ^f  

^a MOORGREEN HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Lundbeck Ltd   (United Kingdom)

^e H LUNDBECK A S   (Denmark)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acetyl cholinesterase inhibitors; behavior; cognition; memantine; MRI; placebo; total brain atrophy

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

AGED; AGITATION; ALZHEIMER DISEASE; ANKLE FRACTURE; ARTICLE; BRAIN ATROPHY; CONSTIPATION; CONTROLLED STUDY; DELUSION; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPLORATORY RESEARCH; FALLING; FEMALE; HEADACHE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HIPPOCAMPUS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; TREATMENT DURATION; VISUAL ACUITY; VITAL SIGN; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84859413111     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-111616     Document Type: Article

References (28)

1. Schmidt R, Ropele S, Pendl B, Ofner P, Enzinger C, Schmidt H, Berghold A, Windisch M, Kolassa H, Fazekas F (2008) Longitudinal multimodal imaging in mild to moderate Alzheimer disease: A pilot study with memantine. J Neurol Neurosurg Psychiatry 79, 1312-1317.
2. Weiner M, Graham SM, Hofbauer RK, Yu SY, Li S, Hsu H-A, Suhy J, Perhach JL (2008) Memantine treatment in patients with Alzheimer's disease is associated with a slower right hippocampal volume loss: An open-label, multi-center trial. Poster presented at the 11th International Conference on Alzheimer's Disease (ICAD); Chicago, IL, USA.
3. Schott JM, Crutch SJ, Frost C, Warrington EK, Rossor MN, Fox NC (2008) Neuropsychological correlates of whole brain atrophy in Alzheimer's disease. Neuropsychologia 46, 1732-1737.
4. Fox NC, Scahill RI, Crum WR, Rossor MN (1999) Correlation between rates of brain atrophy and cognitive decline in AD. Neurology 52, 1687-1689. (Pubitemid 29220648)
5. ICH (1996) ICH Harmonised Tripartite Guideline E6: Guideline for Good Clinical Practice.
6. World Medical, Association (WMA) (1964) Declaration of Helsinki: Ethical principles for medical research involving human subjects, http://www.wma.net/en/ 30publications/10policies/b3/.
7. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosisof Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's Disease. Neurology 34, 939-944. (Pubitemid 14076461)
8. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
9. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A (1980) Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 7, 486-488. (Pubitemid 10073130)
10. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, Wallin A, Ader H, Leys D, Pantoni L, Pasquier F, Erkinjuntti T, Scheltens P, European. Task Force on Age-Related White Matter Changes (2001) A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 32, 1318-1322. (Pubitemid 32530416)
11. Pasquier F, Leys D, Weerts JG, Mounier-Vehier F, Barkhof F, Scheltens P (1996) Inter-and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol 36, 268-272. (Pubitemid 26261656)
12. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steinling M, Wolters EC, Valk J (1992) Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: Diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 55, 967-972.
13. Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, Moody DM, O'Brien MD, Yamaguchi T, Grafman J, Drayer BP, Bennett DA, Fisher M, Ogata J, Kokmen E, Bermejo F, Wolf PA, Gorelick PB, Bick KL, Pajeau AK, Bell MA, DeCarli C, Culebras A, Korezyn AD, Bogousslavsky J, Hartman A, Scheinberg P (1993) Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250-260. (Pubitemid 23060253)
14. van Straaten EC, Scheltens P, Knol DL, van Buchem MA, van Dijk EJ, Hofman PA, Karas G, Kjartansson O, de Leeuw FE, Prins ND, Schmidt R, Visser MC, Weinstein HC, Barkhof F (2003) Operational definitions for the NINDS-AIREN criteria for vascular dementia: An interobserver study. Stroke 34, 1907-1912. (Pubitemid 36944779)
15. Henneman WJ, Sluimer JD, Cordonnier C, Baak MM, Scheltens P, Barkhof F, van der Flier WM (2009) MRI biomarkers of vascular damage and atrophy predicting mortality in a memory clinic population. Stroke 40, 492-498.
16. Freeborough PA, Fox NC (1997) The boundary shift integral: An accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans Med Imag 16, 623-629. (Pubitemid 127767641)
17. Freeborough PA, Fox NC, Kitney RI (1997) Interactive algorithms for the segmentation and quantitationof3-D MRI brain scans. Comput Methods Programs Biomed 53, 15-25. (Pubitemid 27213984)
18. van de Pol LA, Barnes J, Scahill RI, Frost C, Lewis EB, Boyes RG, van Schijndel RA, Scheltens P, Fox NC, Barkhof F (2007) Improved reliability of hippocampal atrophy rate measurement in mild cognitive impairment using fluid registration. Neuroimage 34, 1036-1041. (Pubitemid 46394485)
19. Wechsler D (1987) Wechsler Memory Scale-Revised manual. San Antonio, Texas, The Psychological Corporation.
20. Jensen AR, Rohwer WD Jr (1966) The Stroop color-word test: A review. Acta Psychol (Amst) 25, 36-93.
21. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 141, 1356-1364.
22. Cummings JL (1997) The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology 48 (5 Suppl 6), S10-S16. (Pubitemid 27232698)
23. Frost C, Kenward MG, Fox NC (2004) The analysis of repeated 'direct' measures of change illustrated with an application in longitudinal imaging. Stat Med 23, 3275-3286. (Pubitemid 39462087)
24. Ridha BH, Anderson VM, Barnes. J, Boyes RG, Price SL, Rossor MN, Whitwell JL, Jenkins L, Black RS, Grundman M, Fox NC (2008) Volumetric MRI and cognitive measures in Alzheimer disease: Comparison of markers of progression. J Neurol 255, 567-574.
25. Jack CR Jr, Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K, Xu Y, Shiung M, O'Brien PC, Cha R, Knopman D, Petersen RC (2003) MRI asabiomarkerofdisease progression in a therapeutic trial of milameline for AD. Neurology 60, 253-260. (Pubitemid 36152018)
26. Evans MC, Barnes J, Nielsen C, Kim LG, Clegg SL, Blair M, Leung KK, Douiri A, Boyes RG, Ourselin S, Fox NC; Alzheimer's Disease Neuroimaging Initiative (2010) Volume changes in Alzheimer's disease and mild cognitive impairment: cognitive associations. Eur Radiol 20, 674-682.
27. Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, Perdomo C, Ieni JR, Rogers S (2003) Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 160, 2003-2011. (Pubitemid 39619638)
28. Henneman WJ, Sluimer JD, Cordonnier C, Baak MM, Scheltens P, Barkhof F, van der Flier WM (2009) MRI biomarkers of vascular damage and atrophy predicting mortality in a memory clinic population. Stroke 40, 492-498.